引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 34次   下载 1 本文二维码信息
码上扫一扫!
奥扎格雷钠联合依达拉奉治疗对急性脑梗死患者C反应蛋白及预后的影响
王小刚,叶少君,禹冬菊
0
(新疆军区总医院神经内科;西安市第九医院大明宫铁路社区卫生服务中心)
摘要:
目的 探讨奥扎格雷钠联合依达拉奉对急性脑梗死患者血清C反应蛋白(CRP)及预后的影响。方法 将新疆军区总医院神经内科的98例急性脑梗死住院患者作为观察对象,按照入院治疗的先后顺序分为对照组和观察组各49例。在酌情给予脱水降颅压、对症治疗等常规治疗基础上,对照组给予依达拉奉治疗,观察组采取奥扎格雷钠联合依达拉奉治疗,两组均连续治疗14天。检测两组患者血清CRP水平,并将NIHSS和CSS评分、治疗总有效率及不良反应发生情况等进行比较。 结果 观察组患者治疗14天时血清CRP检测水平较治疗前明显下降(P<0.05),且患者NIHSS、CSS评分均低于对照组(P<0.05);观察组治疗总有效率明显高于对照组(P<0.05),而不良反应发生率却低于对照组(P<0.05)。结论 奥扎格雷钠联合依达拉奉可有效降低急性脑梗死患者血清CRP水平,改善患者神经功能,提高治疗效果,且安全性较高。
关键词:  奥扎格雷钠  依达拉奉  急性脑梗死  C反应蛋白  预后
DOI:
基金项目:
Effect of sodium ozagrel combined with edaravone on C reactive protein and prognosis in patients with acute cerebral infarction
WANG Xiaogang,YE Shaojun,YU Dongju
(Department of Neurology, General Hospital of Xinjiang Military Command;Xi’an Ninth Hospital Daming Palace Railway Community Health Service Center)
Abstract:
Objective To investigate the effect of sodium ozagrel combined with edaravone on serum Creactive protein (CRP) and prognosis in patients with acute cerebral infarction. Methods 98 patients with acute cerebral infarction in neurology department of our hospital were divided into control group and observation group, according to the order of admission treatment, 49 cases in each group. On the basis of routine treatment such as dehydration, hypotension and symptomatic treatment, the control group was treated with edaravone, while the observation group was treated with ozagrel sodium combined with edaravone. Both groups were treated for 14 days. The serum CRP levels of the two groups were detected, and the NIHSS and CSS scores, the total effective rate of treatment and the occurrence of adverse reactions were compared. Results The serum CRP level of patients in the observation group was significantly decreased 14 days after treatment compared with that before treatment (P<0.05), and the NIHSS and CSS scores of patients were lower than those of the control group (P<0.05). The total effective rate of the observation group was significantly higher than that of the control group (P<0.05), while the incidence of adverse reactions was lower than that of the control group (P<0.05). Conclusion Ozagrel sodium combined with edaravone can effectively reduce serum CRP levels, improve neurological function, improve treatment effect, and have higher safety in patients with acute cerebral infarction.
Key words:  Ozagrel sodium  Edaravone  Acute cerebral infarction  C reactive protein  Prognosis

用微信扫一扫

用微信扫一扫